EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Efficacy and Safety of Human Protein C Concentrate in Japanese Patients With Severe Congenital Protein C Deficiency

Katsuyoshi Koh iD, Keiji Nogami iD, Harumi Kakuda iD, Yuri Okimoto, Moeko Hino iD, Chihiro Suzuki iD, Souhei Terashio, Hitoshi Ueda, Shouichi Ohga iD

Pediatrics International · 2026

DOI: 10.1111/ped.70506 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatrics International, 2026. Verfasst von Katsuyoshi Koh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Protein C, Protein C Deficiency. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe congenital protein C deficiency ( SCPCD ) is a rare disorder associated with life‐threatening thrombotic complications. Protein C concentrate is recommended for both acute and long‐term management of SCPCD . However, no efficacy and safety data in Japanese patients have been reported.

Methods

In this extension phase of an open‐label, phase 1/2 clinical trial ( ClinicalTrials.gov : NCT04984889 ), Japanese patients with SCPCD could receive intravenous protein C concentrate for on‐demand treatment, short‐term prophylaxis, or long‐term prophylaxis. Efficacy of on‐demand treatment was assessed using a predefined efficacy evaluation scale. For prophylaxis, efficacy was assessed based on the occurrence of purpura fulminans and thromboembolic complications during prophylaxis treatment. Safety was evaluated by recording adverse events ( AEs ).

Results

All five patients who completed the pharmacokinetics phase of the study participated in this extension phase (mean [ SD ] age: 15.2 [8.9] years). At data cutoff, four patients had received eight on‐demand treatments of protein C concentrate for purpura fulminans; all were rated as effective. Protein C concentrate was administered for short‐term prophylaxis in one patient undergoing tooth extraction, with no thromboembolic complications observed. Six AEs were reported in three patients who received on‐demand treatment; none were treatment‐related. No AEs were observed during short‐term prophylaxis. There were no deaths or AEs leading to treatment discontinuation.

Conclusions

Protein C concentrate was effective for on‐demand treatment and short‐term prophylaxis, and had an acceptable safety profile in this study population. These results support the use of protein C concentrate in the clinical management of patients with SCPCD in Japan. Trial Registration ClinicalTrials.gov registration number: NCT04984889.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein CProtein C DeficiencyHumansFemaleMaleAdolescentJapanChildTreatment OutcomePurpura FulminansEast Asian People

Stichwörter der Autor:innen

SCPCDclinical trialprotein C concentrateprotein C deficiencypurpura fulminans

Substanzen

Protein C

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Pediatrics, Nara Medical University, Kashihara, Japan.
  • Department of Hematology/Oncology, Chiba Children's Hospital, Chiba, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Plasma-Derived Therapies Strategy Unit, PDT R&D, Takeda Pharmaceutical Company Limited, Osaka, Japan.
  • Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.

ORCID-Profile: Katsuyoshi Koh, Keiji Nogami, Harumi Kakuda, Moeko Hino, Chihiro Suzuki, Shouichi Ohga

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Koh, K., Nogami, K., Kakuda, H., Okimoto, Y., Hino, M., Suzuki, C., Terashio, S., Ueda, H., & Ohga, S. (2026). Efficacy and Safety of Human Protein C Concentrate in Japanese Patients With Severe Congenital Protein C Deficiency. Pediatrics International. https://doi.org/10.1111/ped.70506

Vancouver

Koh K, Nogami K, Kakuda H, Okimoto Y, Hino M, Suzuki C, et al. Efficacy and Safety of Human Protein C Concentrate in Japanese Patients With Severe Congenital Protein C Deficiency. Pediatrics International. 2026. doi:10.1111/ped.70506

BibTeX
@article{Koh2026,
  author = {Koh, Katsuyoshi and Nogami, Keiji and Kakuda, Harumi and Okimoto, Yuri and Hino, Moeko and Suzuki, Chihiro and Terashio, Souhei and Ueda, Hitoshi and Ohga, Shouichi},
  title = {Efficacy and Safety of Human Protein C Concentrate in Japanese Patients With Severe Congenital Protein C Deficiency},
  journal = {Pediatrics International},
  year = {2026},
  doi = {10.1111/ped.70506}
}
Kostenlos starten →